Zepbound and Pregnancy: Is Tirzepatide Safe? What the FDA Label Says

The short, careful answer: Zepbound (tirzepatide) is not recommended during pregnancy. The FDA label states plainly that weight loss offers no benefit to a pregnant patient and may cause fetal harm, and it advises that Zepbound should be discontinued once pregnancy is recognized.^[1] Unlike the semaglutide labels (Ozempic/Wegovy), which spell out an explicit "at least 2 months before a planned pregnancy" rule, the current Zepbound label does not state a specific number of weeks or months to stop before trying to conceive^[1] — even though tirzepatide's ~5-to-6-day half-life is shorter than semaglutide's ~1 week.^[1] That gap between "shorter half-life" and "no stated washout number" is one of the most misunderstood facts about Zepbound and pregnancy, and it's the first thing this article untangles. On the data itself: there is limited human pregnancy data, while animal reproduction studies showed adverse developmental effects at clinically relevant exposures^[1] — but the picture on breastfeeding is genuinely more reassuring than for semaglutide, because Lilly has actually published a small human milk pharmacokinetic study.^[1] This article explains exactly what the current Zepbound label says, why there's no numeric preconception rule the way there is for semaglutide, what to do if you conceived while taking it, breastfeeding, birth control, and how the Zepbound (weight-management) label differs in framing from the Mounjaro (type 2 diabetes) label for the same molecule. It is general education, not medical advice — pregnancy and family-planning decisions belong with your OB-GYN or endocrinologist. See our Zepbound drug page and Zepbound side effects guide for the broader profile.

What the FDA Zepbound label actually says

Zepbound's prescribing information addresses pregnancy in §8.1, and the Risk Summary opens with the framing you'd expect from a weight-management drug rather than a diabetes drug: "Weight loss offers no benefit to a pregnant patient and may cause fetal harm."^[1] The label goes on to advise pregnant patients that weight loss is not recommended during pregnancy and to discontinue Zepbound when a pregnancy is recognized.^[1] That is the verbatim, current label language (Revised 02/2026) — quoted directly rather than paraphrased, because the exact wording matters here.

The label then adds the same data-status statement you'll see across the incretin class: "Available data with tirzepatide in pregnant patients are insufficient to evaluate for a drug-related risk of major birth defects, miscarriage, or other adverse maternal or fetal outcomes. Based on animal reproduction studies, there may be risks to the fetus from exposure to tirzepatide during pregnancy."^[1] The Clinical Considerations subsection adds a genuinely useful piece of obstetric context: "Appropriate weight gain based on pre-pregnancy weight is currently recommended for all pregnant patients, including those with obesity or overweight, due to the obligatory weight gain that occurs in maternal tissues during pregnancy."^[1] In plain terms — pregnancy itself calls for weight gain, not the weight loss Zepbound is designed to produce, which is a big part of why the label frames this as a non-starter rather than a case-by-case risk calculation.

One more label detail worth knowing about: Zepbound's Risk Summary states that "the estimated background risk of major birth defects and miscarriage for the indicated population is increased when compared to the general population"^[1] — reflecting that obesity itself is an independent risk factor for adverse pregnancy outcomes, separate from any drug effect. That's a statement about the population the drug is prescribed to, not a statement that tirzepatide itself raises those numbers.

Is there a set washout period before trying to conceive?

This is the single most consequential fact to get right, and it runs counter to a common assumption. The semaglutide labels (Ozempic/Wegovy) state explicitly that patients should stop at least 2 months before a planned pregnancy.^[8] The current Zepbound label does not contain an equivalent numeric instruction — no "stop X weeks before trying to conceive" line appears anywhere in §8.1 or §8.3.^[1] The label's only timing-related instruction in this section is to discontinue Zepbound once pregnancy is recognized, not a preconception planning window.^[1]

That absence is easy to misread as "tirzepatide clears faster, so it doesn't need a washout" — but that's not quite the right takeaway either. Zepbound's §12.3 Pharmacokinetics section states an elimination half-life of approximately 5–6 days in patients with overweight or obesity.^[1] Using the standard pharmacokinetic convention that a drug is largely cleared after about four to five half-lives, that points to near-complete elimination in roughly 25–30 days — genuinely shorter than semaglutide's ~5-week clearance estimate, consistent with tirzepatide's shorter half-life. But "pharmacokinetically clear" and "FDA-recommended preconception interval" are two different things, and only the semaglutide labels commit to the latter as a specific number. Zepbound's label leaves the preconception timing question to clinical judgment rather than stating a rule.

In practice, many prescribers still verbally advise something in the range of 4–8 weeks before actively trying to conceive, reasoning from the half-life the same way this article just did — but that is a clinical extrapolation, not a label requirement, and it is not uniform. If you are planning a pregnancy, the right move is to ask your prescriber directly what interval they recommend for your situation, factoring in your weight-management goals, any other conditions being treated, and how you'll manage contraception until then. Our GLP-1 washout calculator can estimate pharmacokinetic clearance timing based on half-life, and our companion article on Mounjaro and the preconception washout question walks through the identical pharmacokinetics (Mounjaro is the same molecule) in more depth, since the diabetes-brand label raises the same "no stated number" issue.

Why — animal reproductive-toxicity findings and limited human data

The caution rests on the same two-part logic as the rest of the GLP-1/GIP class: human pregnancy data are limited, and the animal data raise real concerns.

On the animal side, Zepbound's §8.1 Data subsection reports that in pregnant rats given tirzepatide during organogenesis at doses spanning roughly 0.03- to 0.5-fold the maximum recommended human dose (by AUC), there were increased incidences of external, visceral, and skeletal malformations, increased developmental variations, and decreased fetal weights — effects that coincided with reduced maternal body weight and food intake at the highest dose tested.^[1] In pregnant rabbits, tirzepatide at doses as low as 0.01-fold the maximum recommended human dose caused pharmacologically-mediated gastrointestinal effects that led to maternal mortality or abortion in a few animals at every dose level tested, with reduced fetal weights at the highest dose.^[1] The current label also reports a pre- and post-natal rat study: offspring of mothers given the highest tested dose throughout gestation and lactation had statistically significant lower body weight that persisted from postnatal day 7 through postnatal day 126 in males and day 56 in females.^[1] Animal findings don't automatically translate to humans — and the label is explicit that many of these effects tracked with the mother eating and gaining less, a known pharmacological effect of the drug itself — but in the absence of reassuring human data, they carry real weight in how the label is written.

On the human side, the label states plainly that available tirzepatide pregnancy data are insufficient to evaluate a drug-related risk of major birth defects, miscarriage, or other adverse maternal or fetal outcomes.^[1] "Insufficient to evaluate" is not the same as "shown to be safe" — it means the question hasn't been answered with enough data, which is exactly why Lilly maintains an active pregnancy exposure registry (below) to start closing that gap.

If you conceived while taking Zepbound

First, the reassuring framing: discovering you are pregnant while on Zepbound is not, by itself, a reason to panic. "Insufficient data" cuts both ways — harm has not been demonstrated in humans either. What matters is acting promptly and through your clinician.

The labeled guidance is direct: discontinue Zepbound when pregnancy is recognized.^[1] Practically, that means:

• Stop the medication and contact your OB-GYN (and your prescriber) promptly. Since weight loss offers no pregnancy benefit and pregnancy itself calls for appropriate weight gain, there is no clinical reason to continue Zepbound once you know you're pregnant.^[1]
• Consider reporting the exposure to Lilly's pregnancy exposure registry. The current label states there will be a pregnancy exposure registry monitoring outcomes in patients exposed to Zepbound during pregnancy, and that patients and providers are encouraged to contact Eli Lilly at 1-800-LillyRx (1-800-545-5979).^[1] Reporting helps close the very human-data gap that drives the "insufficient to evaluate" language above.
• Don't assume harm — and don't make any irreversible decision based on the medication alone. The available data are insufficient to establish a specific risk; your OB-GYN is the right person to discuss monitoring for your individual pregnancy.

The single most useful sentence to carry away: stop it, tell your provider, and consider the registry — a deliberate, informed step, not an emergency.

Breastfeeding on Zepbound

This is one area where Zepbound's label is genuinely more informative than semaglutide's. Rather than "no human data," Lilly ran a single-dose clinical lactation study: after a single 5 mg subcutaneous dose in 11 healthy lactating adults, tirzepatide was undetectable in 164 of 171 breast-milk samples collected over a 28-day sampling window (limit of detection: 4 ng/mL).^[1] In the remaining 7 samples where it was detected, the cumulative amount was less than 0.02% of the maternal dose, with the last measurable concentration occurring 5 days post-dose.^[1] The label notes the AUC in breast milk couldn't even be calculated because concentrations were so consistently low.^[1]

That's a reassuring pharmacokinetic picture — but the label still frames breastfeeding as a clinical decision, not a green light: "There are no available data on the effects of tirzepatide on the breastfed infant or on milk production. The developmental and health benefits of breastfeeding should be considered along with the mother's clinical need for ZEPBOUND and any potential adverse effects on the breastfed infant."^[1] In other words, "barely detectable in milk" answers the exposure question but not the effects question — infant outcomes from that small exposure haven't been separately studied. If you are breastfeeding or planning to, raise it specifically with your OB-GYN, pediatrician, or endocrinologist before starting or restarting Zepbound. For the parallel data on the diabetes-brand label, see Mounjaro and breastfeeding — the underlying pharmacokinetic study is the same, since it's the same molecule.

Birth control and Zepbound

Tirzepatide carries a more formal, more specific oral-contraceptive warning than semaglutide does — and it's directly relevant to pregnancy planning because it's the mechanism behind most unintended periconceptional exposure. Zepbound's §8.3 states: "Use of ZEPBOUND may reduce the efficacy of oral hormonal contraceptives due to delayed gastric emptying. This delay is largest after the first dose and diminishes over time. Advise patients using oral hormonal contraceptives to switch to a non-oral contraceptive method, or add a barrier method of contraception for 4 weeks after initiation with ZEPBOUND and for 4 weeks after each dose escalation."^[1]

Because Zepbound's standard titration schedule adds a dose increase roughly every 4 weeks for the first several months, that 4-weeks-per-escalation window can effectively stack up to an extended stretch of needing backup contraception if you're relying on the pill, patch, or ring. Non-oral methods (implant, IUD, injection) aren't affected by gastric emptying and sidestep the issue entirely. This warning is a genuine tirzepatide-specific detail — it's one reason unintended pregnancy is a more commonly discussed scenario on tirzepatide than on some other GLP-1s. See our full breakdown: the Mounjaro and Zepbound birth control warning.

Fertility and unintended pregnancy on Zepbound

You may have seen coverage of unexpected pregnancies among people on GLP-1-class drugs (often framed around Ozempic, but the same logic applies to tirzepatide). Two mechanisms explain most of it, and neither makes Zepbound a fertility treatment: it is not FDA-approved to treat infertility.

• Weight loss can restore ovulation, especially in PCOS. A 2026 narrative review of GLP-1 receptor agonists, fertility restoration, and reproductive safety in women of reproductive age (Abedi and colleagues, Journal of Clinical Medicine, PMID 42122936) discusses how meaningful weight loss in obesity-related anovulation, including PCOS, can help restore more regular ovulation — a downstream effect of weight loss, not a direct fertility action of tirzepatide.^[7]
• Reduced oral-contraceptive effectiveness from the delayed-gastric-emptying mechanism described above is the other major contributor — an "unexpected" pregnancy can simply be a pill that didn't absorb as expected during the 4-week windows around initiation and dose changes.^[1]

What does the real-world data on unintentional periconceptional GLP-1 exposure actually show? Two 2026 nationwide registry cohort studies looked at this directly. A Danish nationwide cohort (Hviid and colleagues, Human Reproduction Open, PMID 41852577) examined obstetric outcomes after periconceptional GLP-1 receptor agonist exposure.^[2] A Taiwan nationwide cohort using the National Health Insurance Research Database (Chou and colleagues, Diabetes, Obesity and Metabolism, PMID 41346258) examined the same question in unintentional periconceptional exposure.^[3] Both are observational registry studies capturing real-world unintentional exposure (largely the contraception-failure scenario above); neither identified a clear-cut teratogenic signal at the cohort level, but both authors explicitly caveated limited sample sizes for specific outcomes and did not endorse intentional GLP-1 use during pregnancy.^[2][3] A broader 2023 systematic review of GLP-1 and SGLT2 use in pregnancy and lactation (Muller and colleagues, Frontiers in Endocrinology, PMID 37881498) reached the same conclusion: human evidence remains sparse, and decisions must be individualized.^[4] The 2025 EASO Position Statement on women with obesity across the reproductive life (Filippi-Arriaga and colleagues, Obesity Facts, PMID 40544836) calls for prospective preconception, pregnancy, and postpartum registries — exactly the gap Lilly's own Zepbound pregnancy exposure registry is designed to help fill.^[5]

The practical implication runs the opposite direction from the headlines: if you are on Zepbound and do not want to become pregnant, be more attentive to reliable, non-oral contraception during the windows the label flags — because fertility may have quietly improved from the weight loss itself, even as the drug must be avoided in pregnancy. If you are trying to conceive, the conversation to have is about discontinuation timing (see above) with your OB-GYN or endocrinologist, not about using Zepbound to help you conceive.

Zepbound vs. Mounjaro — does the diabetes brand's label differ?

Zepbound and Mounjaro are the identical molecule, tirzepatide, sharing the same §12.3 pharmacokinetics (~5–6 day half-life) and largely the same animal reproductive-toxicity data.^[1][6] But the two labels' §8.1 Risk Summaries are written for different indicated populations, and the framing genuinely differs — the same pattern seen between Wegovy and Ozempic for semaglutide. Zepbound's Risk Summary leads with "weight loss offers no benefit to a pregnant patient and may cause fetal harm" because there's no competing clinical justification for intentional weight loss during pregnancy.^[1] Mounjaro's Risk Summary, for the type-2-diabetes indication, instead says the drug "should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus"^[6] — because poorly controlled diabetes carries its own well-documented pregnancy risks, so the diabetes-management label leaves room for an individualized benefit/risk call that the weight-management label doesn't need to make.

Neither label states a numeric preconception washout window; both discontinuation decisions are handed to the prescriber. For the deeper dive into the diabetes-brand label specifically — including the full verbatim animal-data quotes as filed under Mounjaro's application — see Mounjaro and pregnancy: the FDA label and the preconception washout question, and for a side-by-side of how the two labels are organized generally, see the Mounjaro/Zepbound FDA prescribing information explained.

Key guidance at a glance

Bottom line — plan with your clinician

• Zepbound (tirzepatide) is not recommended during pregnancy. The label says weight loss offers no benefit in pregnancy and may cause fetal harm, and to discontinue once pregnancy is recognized.^[1]
• Unlike semaglutide, the Zepbound label states no specific preconception washout number. Its ~5–6 day half-life implies faster pharmacokinetic clearance (~25–30 days by the standard 5-half-life rule), but that's a clinical extrapolation, not a labeled requirement — ask your prescriber for a specific plan.^[1]
• The caution is driven by limited human data plus adverse animal reproductive findings — an unanswered safety question, which in pregnancy defaults to avoidance.^[1]
• Conceived on it? Stop, call your provider, and consider the pregnancy exposure registry (1-800-LillyRx) — don't panic.^[1]
• Breastfeeding data are more reassuring than for semaglutide (largely undetectable in milk in a small study) but infant-effect data don't exist, so it's still an individual clinical call.^[1]
• The 4-week backup-contraception rule around initiation and each dose escalation is real and tirzepatide-specific — a common source of unintended periconceptional exposure.^[1]

If you are weighing whether and how to use Zepbound under proper medical supervision — including timing it around family planning — a legitimate provider will take a full history, discuss contraception and pregnancy intentions, and follow up. Compare the best tirzepatide providers, see the Zepbound and Mounjaro drug pages plus our Zepbound side effects guide for the full profile, and use the GLP-1 washout calculator to estimate clearance timing. Pregnancy and family-planning decisions belong with your OB-GYN or endocrinologist — this page is general education to bring to that conversation, not a substitute for it.

Further reading

• Mounjaro and pregnancy: the FDA label and the preconception washout question — the diabetes-brand companion, same molecule, verbatim label quotes.
• The Mounjaro and Zepbound birth control warning — full breakdown of the 4-week backup-contraception rule.
• GLP-1 missed-dose rules by drug — what to do if you skip a Zepbound injection.
• Mounjaro and breastfeeding — the same human milk pharmacokinetic study, discussed in the diabetes-brand context.
• GLP-1s, pregnancy, PCOS, and fertility — the broader class-level evidence on fertility restoration.
• GLP-1 washout calculator (tool) — estimate pharmacokinetic clearance timing by drug and dose.